Literature DB >> 24085574

Breast cancer management in the elderly.

M Luque1, F Arranz, J F Cueva, A de Juan, P García-Teijido, L Calvo, I Peláez, A García-Palomo, J García-Mata, S Antolín, L García-Estévez, Y Fernández.   

Abstract

The increase in life expectancy in the western world means that we are faced with patients diagnosed with breast cancer in old age with increasing frequency. The management of these cases is a challenge for the oncologist, who must take into account the conditions associated with advanced age and the lack of trials in this population. In this review, we addressed the incorporation of geriatric assessment methods that may be useful in making decisions, the particular biological characteristics of breast cancer in elderly patients and their treatment in both localized and advanced disease. Finally, we collected recommendations based on scientific evidence regarding the monitoring and life-style after finishing treatment.

Entities:  

Mesh：

Year:  2013        PMID： 24085574     DOI： 10.1007/s12094-013-1113-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  97 in total

1.  Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update).

Authors:  Eva Grunfeld; Sukhbinder Dhesy-Thind; Mark Levine
Journal:  CMAJ       Date:  2005-05-10       Impact factor: 8.262

Review 2.  Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).

Authors:  D Hind; L Wyld; C B Beverley; M W Reed
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

3.  Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.

Authors:  Emilio Bajetta; Giuseppe Procopio; Luigi Celio; Luca Gattinoni; Silvia Della Torre; Luigi Mariani; Laura Catena; Riccardo Ricotta; Raffaella Longarini; Nicoletta Zilembo; Roberto Buzzoni
Journal:  J Clin Oncol       Date:  2005-02-14       Impact factor: 44.544

4.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

Review 5.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Authors:  Eitan Amir; Bostjan Seruga; Saroj Niraula; Lindsay Carlsson; Alberto Ocaña
Journal:  J Natl Cancer Inst       Date:  2011-07-09       Impact factor: 13.506

6.  Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.

Authors:  Edith A Perez; Maria Koehler; Julie Byrne; Alaknanda J Preston; Erica Rappold; Michael S Ewer
Journal:  Mayo Clin Proc       Date:  2008-06       Impact factor: 7.616

7.  Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Authors:  Sandra M Swain; Fredrick S Whaley; Michael S Ewer
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

8.  Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

Authors:  Stephen Chia; William Gradishar; Louis Mauriac; Jose Bines; Frederic Amant; Miriam Federico; Luis Fein; Gilles Romieu; Aman Buzdar; John F R Robertson; Adam Brufsky; Kurt Possinger; Pamela Rennie; Francisco Sapunar; Elizabeth Lowe; Martine Piccart
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

9.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Authors:  Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes
Journal:  Lancet Oncol       Date:  2010-11-17       Impact factor: 41.316

10.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Authors:  R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard
Journal:  Lancet       Date:  2011-12-05       Impact factor: 79.321
View more
  2 in total

1.  Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.

Authors:  Anna R Schreiber; Jodi Kagihara; Megan Eguchi; Peter Kabos; Christine M Fisher; Elisabeth Meyer; Elizabeth Molina; Lavanya Kondapalli; Cathy J Bradley; Jennifer R Diamond
Journal:  Breast Cancer Res Treat       Date:  2021-10-27       Impact factor: 4.872

Review 2.  Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer.

Authors:  M D Torregrosa-Maicas; S Del Barco-Berrón; A Cotes-Sanchís; L Lema-Roso; S Servitja-Tormo; R Gironés-Sarrió
Journal:  Clin Transl Oncol       Date:  2022-02-01       Impact factor: 3.340
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.